On Feb. 26, 2020, Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.

Tonix is developing TNX-801 – a live horsepox virus vaccine for percutaneous administration — as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a vaccine against monkeypox. Tonix’s proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents.

Southern Research and Tonix said the new research collaboration will develop and test a potential horsepox vaccine that expresses protein from the virus that causes COVID, a SARS-CoV-2, to protect against the disease. There are currently no vaccines to protect against COVID-19, which may cause serious complications. The SARS-CoV-2 is reportedly highly infectious and is associated with a significant rate of mortality.

Under the terms of the research collaboration, Southern Research will test one or more vaccine constructs in the Tonix horsepox vector that express one or more proteins or protein fragments from COVID-19. The collaboration seeks to leverage Tonix’s horsepox vaccine technology that was originally developed to protect against smallpox but has capabilities as a vector for other infectious diseases.

Tonix has previously reported that horsepox has efficacy as a vaccine and good tolerability in mice and cynomolgus macaques. Horsepox is closely related to vaccinia vaccines, which are a group of orthopoxviruses that have been used as smallpox vaccines. Some vaccinia vaccines have been engineered to express coronavirus proteins and to elicit vaccine responses successfully in the past.